Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.44, $0.27 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.49 billion.

GUIDANCE:

Gilead Sciences sees FY2019 revenue of $21.3-21.8 billion, versus the consensus of $21.74 billion.

• Product Gross Margin 85% - 87%

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target